EORTC QLQ‐C30
fatigue, Cancer
CANCER
Baseline means for the QLQ‐C30 are presented in Table Change from Baseline for EORTC QLQ‐C30. CI, confidence interval; EORTC QLQ‐C30, European Organization for Treatment of Cancer Quality of Life Questionnaire Core 30 items; GHS/QOL, global health status/quality of life; LS, least squares.In the tislelizumab arm, the physical functioning domain score maintained at week 12 (LS mean change: −0.6 [95% CI: −2.04 to 0.75]) and week 18 (LS mean change: −0.7 [95% CI: −2.32 to 0.82]), while worsening in the docetaxel arm at both week 12 (LS mean change: −2.5 [95% CI: −4.64 to −0.35]) and week 18 (LS mean change: −4.7 [95% CI: −7.42 to −2.06]). The difference in change from baseline between the two arms was not significant at week 12 (difference in LS mean change: 1.8 [95% CI: −0.50 to 4.19, The fatigue symptom scale score improved in the tislelizumab arm at both week 12 (LS mean change: −1.9 [95% CI: −3.50 to −0.26]) and week 18 (LS mean change: −1.9 [95% CI: −3.67 to −0.16]). In the docetaxel arm fatigue increased at week 12 (LS mean change: 1.3 [95% CI: −1.28 to 3.83]) and week 18 (3.0 [95% Cl: −0.04 to 6.07]). The difference in fatigue scores between the two arms was significant at both week 12 (difference in LS mean change: −3.2 [95% CI: −5.95 to −0.37, 